Cardiovascular Disease Incidence and Risk Mitigation in Patients with Locally Advanced or Metastatic Prostate Cancer on ADT : Episode 16

Video

March 3, 2023

Considerations For ADT Selection And Patient Education on Treatment-Related AEs

Expert insight on selection of androgen deprivation therapy and how related adverse events may be communicated to patients in advance.

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

EP: 1.Cardiovascular Disease Risk in Men with Prostate Cancer

EP: 2.Examining the Data From Key Clinical Trials, and Practical Strategies

EP: 3.Strategies for Mitigating Cardiovascular Risk

EP: 4.Summary and Case Study

EP: 5.A Medical Oncologist Reflects on a Typical Prostate Cancer Patient

EP: 6.A Urologist Reflects on a Typical Prostate Cancer Patient

EP: 7.A Cardiologist Reflects on a Typical Prostate Cancer Patient

EP: 8.Practice-Related And Provider-Patient Communication Strategies For Prostate Cancer Care

EP: 9.A Cardiologist’s Perspective on Cardiovascular Risk Assessment in Prostate Cancer

EP: 10.A Medical Oncologist’s Perspective on Cardiovascular Risk Assessment in Prostate Cancer

EP: 11.Typical Examinations And Tests For Cardiovascular Risk Assessment in a Cardiology Practice

EP: 12.Typical Examinations And Tests For Cardiovascular Risk Assessment in an Oncology Practice

EP: 13.A Cardiologist’s Recommended Interventions For Cardiovascular Risk Mitigation

EP: 14.A Medical Oncologist’s Recommended Interventions For CV Risk Mitigation

EP: 15.Strategies For Communicating Cardiovascular Risk to Patients Starting on ADT

Now Viewing

EP: 16.Considerations For ADT Selection And Patient Education on Treatment-Related AEs

EP: 17.A Urologist’s Approach to Followup For Patients on ADT And Practice Communication Strategies

EP: 18.A Cardiologist’s Approach to Followup For Patients on ADT and Strategies in Multidisciplinary Care

EP: 19.A Urologist Reacts to AbbVie’s Educational Video: Key Takeaways And Clinical Impact

EP: 20.A Cardiologist Reacts to AbbVie’s Educational Video: Key Takeaways And Clinical Impact

January 2023 AbbVie Inc. Company Confidential

Related Content

March 28th 2025

FDA approves expanded label for 177Lu-PSMA-617 in mCRPC

Hannah Clarke

The approval is supported by positive data from the phase 3 PSMAfore trial.

February 29th 2024

Dr. Murphy on increasing diversity in cancer clinical trials

Urology Times staff

In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.

March 22nd 2025

Data reinforce isodose MHFRT as standard of care radiotherapy regimen

Hannah Clarke

“These findings reinforce isodose MHFRT as the standard of care, offering the same cancer control as conventional treatment but with fewer side effects than dose-escalated MHFRT,” says Amar U. Kishan, MD.

January 11th 2024

Dr. Schwen on focal therapies for prostate cancer

Cleveland Clinic

Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.

March 20th 2025

Trial launches of CBP/p300 inhibitor in mCRPC

Hannah Clarke

Pocenbrodib is an oral, small molecule designed to inhibit the proteins CREBBP/EP300, which activate genes that promote cancer cell growth and proliferation.

March 17th 2025

Exercise may improve erectile function in men with prostate cancer

Hannah Clarke

“The study suggests that exercise would be an effective intervention for men with prostate cancer who express concern about sexual dysfunction, and that exercise medicine should be considered a key part of their treatment,” says Daniel Galvão, PhD.